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    The respiratory bacterial infection caused by Bordetella pertussis (whooping cough) is the 
only vaccine-preventable disease whose incidence has been increasing over the last 3 
decades.  To better understand the resurgence of this infection, a baboon animal model of 
pertussis infection has been developed. Naïve baboons that recover from experimental 
pertussis infection are resistant both to clinical disease and to airway colonization when re-
challenged.  In contrast, animals vaccinated with acellular pertussis vaccine and experimentally 
challenged do not develop disease, but airways remain colonized for 4-6 weeks.  We explored 
the possibility that the IgG antibody response to pertussis infection is qualitatively different from 
antibodies induced by acellular pertussis vaccination.  
     IgG was purified from pertussis-convalescent baboons shown to be resistant to pertussis 
disease and airway colonization. Purified IgG contained high titers to pertussis toxin, pertactin, 
and filamentous hemagglutinin.  This pertussis-immune IgG or control IgG was passively 
transferred to naïve, juvenile baboons before experimental airway pertussis inoculation.  The 
control animal that received normal IgG developed a typical symptomatic infection including 
leukocytosis, cough and airway colonization for 4 weeks.  In contrast, baboons that received 
convalescent IgG maintained normal WBC counts and were asymptomatic.  However, despite 
remaining asymptomatic, their airways were colonized for 4-6 weeks with B. pertussis.  All 
animals developed IgG and IgA anti-pertussis antibody responses.  Interestingly, the clearance 
of B. pertussis from airways coincided with the emergence of a serum anti-pertussis IgA 
response.   
    These studies demonstrate that passive administration of pertussis-specific IgG from 
previously infected animals can prevent clinical disease but does not affect prolonged airway 
colonization with B. pertussis.  This outcome is similar to that observed following acellular 
pertussis vaccination.  Understanding immune mechanisms—other than IgG—that are capable 
of preventing airway colonization with B. pertussis will be critical for developing more effective 
vaccines to prevent whooping cough.   
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